Shares of Hypermarcas (OTCMKTS:HYPMY – Get Free Report) reached a new 52-week low on Monday. The stock traded as low as $3.39 and last traded at $3.39, with a volume of 31,720 shares. The stock had previously closed at $5.40.
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group raised shares of Hypermarcas to a “strong-buy” rating in a research report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy”.
Read Our Latest Research Report on HYPMY
Hypermarcas Stock Down 27.8%
The firm has a market cap of $2.75 billion, a P/E ratio of 7.80 and a beta of 0.65. The firm’s fifty day moving average is $4.68 and its 200 day moving average is $4.44. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.26 and a current ratio of 1.86.
Hypermarcas (OTCMKTS:HYPMY – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.01. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. As a group, equities research analysts anticipate that Hypermarcas will post 0.51 earnings per share for the current fiscal year.
Hypermarcas Company Profile
Hypermarcas SA was a Brazilian consumer-health and pharmaceutical company that later changed its corporate name to Hypera SA The company was established as a diversified consumer-products business and, over time, shifted its focus toward pharmaceuticals and healthcare products.
Hypera develops, manufactures and markets prescription medicines, generic and branded-generic drugs, over-the-counter products, vitamins and nutritional supplements. Its portfolio has included well-known Brazilian consumer-health brands such as Neosaldina, Doril, Engov, Benegrip and Addera D3, serving categories including pain relief, cold and flu treatment, digestive health and vitamins.
The company’s principal market is Brazil, where its products are distributed through pharmacies, retailers and other healthcare channels.
See Also
- Five stocks we like better than Hypermarcas
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
- Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
- Insiders Are Selling These 5 AI Stocks—Should You Worry?
- 3 Companies With Room to Pass on Costs to Manage Inflation
Receive News & Ratings for Hypermarcas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypermarcas and related companies with MarketBeat.com's FREE daily email newsletter.
